Key result
Subclinical stent edge effects post-PCI predict ~280% higher long-term target lesion failure risk.
Why the study?
Does subclinical stent edge effect (sDES-EE) at 1 year predict stent edge target lesion failure (EE-TLF) at 5 years in patients after drug-eluting stent implantation?
Cohort
Does subclinical stent edge effect (sDES-EE) at 1 year predict stent edge target lesion failure (EE-TLF) at 5 years in patients after drug-eluting stent implantation?
Absolute Event Rate: 15.6% vs 4.1%
p-value: p=0.001
Subclinical stent edge effects with MLA reduction ≥ 25% at 1 year after PCI independently predict stent edge target lesion failure at 5 years, driven by lipid progression on OCT.
, p = 0.025) and lipid percent atheroma volume (3.92 ± 1.34% vs. -1.22 ± 0.78%, p = 0.029). EE-TLF at 5 years was significantly higher in the sDES-EE group than in the non-sDES-EE group (15.6% vs. 4.1%, p = 0.001). sDES-EE with MLA reduction ≥ 25% at the stent edge at 1 year after PCI was an independent predictor of EE-TLF at 5 years, which was mainly caused by the progression of lipid components measured by OCT. TRIAL REGISTRATION: ClinicalTrials.gov. Number NCT02140801. STUDY REGISTRATION: http://www. CLINICALTRIALS: gov . identifier: NCT02140801.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) conducted a cohort in Drug-eluting stent implantation. Subclinical stent edge effects (sDES-EE) vs. Non-sDES-EE was evaluated on EE-TLF at 5 years (p=0.001). Subclinical stent edge effects with MLA reduction ≥25% at 1 year post-PCI independently predicted higher 5-year target lesion failure compared to no edge effects (15.6% vs. 4.1%, p=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: